A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients

2020 Baud, 2020, Real estimates of mortality following COVID-19 infection, Lancet Infect Dis, 20, 773, 10.1016/S1473-3099(20)30195-X Grein, 2020, Compassionate use of remdesivir for patients with severe covid-19, N Engl J Med, 382, 2327, 10.1056/NEJMoa2007016 Wang, 2020, Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China, MedRxiv Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783 Shanmugaraj, 2020, Allergy and immunology perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19), Asian Pac J Allergy Immunol, 38, 8 Lan, 2020, Positive RT-PCR test results in patients recovered from COVID-19, JAMA, 323, 1502, 10.1001/jama.2020.2783 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z Jin, 2020, Virology, epidemiology, pathogenesis, and control of covid-19, Viruses, 12, 372, 10.3390/v12040372 Li, 2020, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharm Anal, 10, 102, 10.1016/j.jpha.2020.03.001 Chen, 2020, Emerging coronaviruses: genome structure, replication, and pathogenesis, J Med Virol, 92, 418, 10.1002/jmv.25681 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Prompetchara, 2020, Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic, Asian Pac J Allergy Immunol, 38, 1 Cao, 2020, COVID-19: immunopathology and its implications for therapy, Nat Rev Immunol, 20, 269, 10.1038/s41577-020-0308-3 Shi, 2020, COVID-19 infection: the perspectives on immune responses, Cell Death Differ, 27, 1451, 10.1038/s41418-020-0530-3 Lim, 2020, Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR, J Kor Med Sci, 35, e79, 10.3346/jkms.2020.35.e79 Cao, 2020, A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19, N Engl J Med, 382, 1787, 10.1056/NEJMoa2001282 Cheng, 2020, Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan, J Microbiol Immunol Infect, 53, 488, 10.1016/j.jmii.2020.03.032 Holshue, 2020, First case of 2019 novel coronavirus in the United States, N Engl J Med, 382, 929, 10.1056/NEJMoa2001191 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 56, 105949, 10.1016/j.ijantimicag.2020.105949 Magagnoli, 2020, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, Med, 1, 114, 10.1016/j.medj.2020.06.001 Chen, 2020, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J Zhejiang Univ (Med Sci), 49, 1 Funck-Brentano, 2020, Response to the editorial “COVID-19 in patients with cardiovascular diseases”, Arch Cardiovasc Dis, 113, 367, 10.1016/j.acvd.2020.04.001 Sun, 2020, Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by hospital pharmacovigilance system, Clin Pharmacol Ther, 108, 791, 10.1002/cpt.1866 Roback, 2020, Convalescent plasma to treat COVID-19: possibilities and challenges, JAMA, 323, 1561, 10.1001/jama.2020.4940 Xu, 2020, Effective treatment of severe COVID-19 patients with Tocilizumab, Proc Natl Acad Sci USA, 117, 10970, 10.1073/pnas.2005615117 Kruse, 2020, Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China, F1000Res, 9, 72, 10.12688/f1000research.22211.2 Ulrich, 2020 Stebbing, 2020, COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect Dis, 20, 400, 10.1016/S1473-3099(20)30132-8 Golchin, 2020 Iyer, 2009, Mesenchymal stem cells and inflammatory lung diseases, Panminerva Med, 51, 5 Metcalfe, 2020, Mesenchymal stem cells and management of COVID-19 pneumonia, Med Drug Discov, 5, 100019, 10.1016/j.medidd.2020.100019 Johnson, 2017, Concise review: mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes, Stem Cells Transl Med, 6, 1141, 10.1002/sctm.16-0415 Abraham, 2020, Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome, Stem Cells Transl Med, 9, 28, 10.1002/sctm.19-0205 Morrison, 2017, Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer, AtsjournalsOrg, 196, 1275 Zhen, 2008, Mesenchymal stem cells transplantation protects against rat pulmonary emphysema, Front Biosci, 13, 3415, 10.2741/2936 Khoury, 2020, Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19, Eur Respir J, 55, 2000858, 10.1183/13993003.00858-2020 Chen, 2020, Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment, Engineering, 6, 1153, 10.1016/j.eng.2020.02.006 Leng, 2020, Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia, Aging Dis, 11, 216, 10.14336/AD.2020.0228 Raza, 2020, “Primed” mesenchymal stem cells: a potential novel therapeutic for COVID19 patients, Stem Cell Rev Rep, 17, 153, 10.1007/s12015-020-09999-0 Bari, 2020, Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use, Cells, 9, 924, 10.3390/cells9040924 Zhou, 2019, The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity, J Clin Med, 8, 1025, 10.3390/jcm8071025 Iyer, 2008, Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies, Expert Opin Biol Ther, 8, 569, 10.1517/14712598.8.5.569 Yi, 2019, Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3, Exp Cell Res, 383, 111454, 10.1016/j.yexcr.2019.05.035 Song, 2017, Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis, Stem Cells, 35, 1208, 10.1002/stem.2564 wei, 2019, Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p, Eur J Pharmacol, 852, 68, 10.1016/j.ejphar.2019.01.022 Liang, 2020, Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells, Medicine, 99, e21429, 10.1097/MD.0000000000021429 Zhang, 2020, Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia, Stem Cell Res Ther, 11, 207, 10.1186/s13287-020-01725-4 2020 Antunes, 2014, Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema, Respir Res, 15, 118, 10.1186/s12931-014-0118-x Cardenes, 2019, Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model, BMJ Open Respir Res, 6, 308, 10.1136/bmjresp-2018-000308 Behnke, 2020, MSC based therapies—new perspectives for the injured lung, J Clin Med, 9, 682, 10.3390/jcm9030682 Chrzanowski, 2020, Can stem cells beat COVID-19: advancing stem cells and extracellular vesicles toward mainstream medicine for lung injuries associated with SARS-CoV-2 infections, Front Bioeng Biotechnol, 8, 554, 10.3389/fbioe.2020.00554 Gardin, 2020, Could mesenchymal stem cell-derived exosomes Be a therapeutic option for critically ill COVID-19 patients?, J Clin Med, 9, 2762, 10.3390/jcm9092762 Sengupta, 2020, Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19, Stem Cells Dev, 29, 747, 10.1089/scd.2020.0080 Olsen, 2018, Peak MSC—are we there yet?, Front Med, 5, 178, 10.3389/fmed.2018.00178